NCT02314273View on ClinicalTrials.gov

Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Pancytopenia Due to Chemotherapy
Interventions
DRUG

rhIL-11

patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL

Trial Locations (5)

200127

Shanghai Children's Medical Center, Shanghai

Unknown

Beijing Children's Hospital, Beijing

Nanjing Children's Hospital, Nanjing

Soochow University Affiliated Children's Hospital, Suzhou

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
collaborator

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY

lead

Shanghai Children's Medical Center

OTHER

NCT02314273 - Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL | Biotech Hunter | Biotech Hunter